Clinical trials: Therapy Resistant Depression
Treatment Resistant Depression
Dutch-Depression Outcome Trial Comparing 5 Day Multi Daily Neuronavigated Theta Burst Sessions With 6 Weeks rTMS
INTRODUCTION Recent findings from three small studies (total n=59) suggest that three changes in repetitive Transcranial Magnetic Stimulation (rTMS) protocols, called the Stanford Neuromodulation Therapy (SNT) protocol…
- Trial name
- DDOTT (NCT05900271)
- Testing
- rTMS, iTBS
- Where
- 4 sites in Netherlands
- Volunteers
- 108 people
- Sponsor
- Amsterdam UMC, location VUmc
Treatment Resistant Depression
Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)
The main purpose of this study is to assess the efficacy and safety of daily and intermittent dosing of MK-1942 compared to placebo among participants with Treatment-Resistant Depression (TRD) on a stable course of antidepressant…
- Trial name
- NCT04663321
- Testing
- MK-1942
- Where
- 45 sites in United States
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Depression
Efficacy and Safety of Antidepressant Augmentation With Lamotrigine
This study reports a clinical trial evaluating lamotrigine safety and efficacy as an antidepressant augmentation agent in treatment resistant depression, therefore adding more empirical evidence to the limited number of studies…
- Trial name
- NCT00652171
- Testing
- Lamotrigine, Amide
- Volunteers
- 34 people
- Sponsor
- Institute of Social Security of the Civil Servants of Minas Gerais
Depressive Disorder
Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients
Phase III, open label, randomised, multicentre, blind for evaluators clinical trial to evaluate the efficacy of esketamine nasal spray at flexible dosis compared to aripiprazole in elderly participants (>60 years) who suffer from…
- Trial name
- CESAR (NCT07153406)
- Testing
- Experimental regimen, Control regimen
- Where
- 9 sites in Spain
- Volunteers
- 220 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Treatment Resistant Depression, Generalized Anxiety Disorder
An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay
Genomind has developed and introduced a battery of genetic tests, the Genecept Assay, which clinicians can administer to patients using a simple saliva sample technique. The present study proposes to enroll 1.
- Trial name
- COM-1 (NCT01507155)
- Testing
- Genecept Assay
- Where
- United States
- Volunteers
- 685 people
- Sponsor
- Genomind, LLC
Treatment-resistant Depression
Action of Ketamine in Treatment-Resistant Depression
Depression carries the largest burden of all medical disorders in middle to high income countries, as determined by the World Health Organization.
- Trial name
- NCT01945047
- Testing
- Ketamine, Midazolam
- Where
- Canada
- Volunteers
- 46 people
- Sponsor
- University of Ottawa
Major Depressive Disorder
Comparison of Anodal Transcranial Direct Current Stimulation (t-DCS) and Sham Stimulation in Patients With Treatment-resistant Depression
Major depressive disorder (MDD) is a significant public health problem. Existing treatment modalities are not always sufficient to alleviate this disorder. Treatment refractoriness is a common clinical problem.
- Trial name
- NCT02141776
- Testing
- Transcranial direct current stimulation (t-DCS)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Florida
Treatment Resistant Depression
Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine
This study aims to assess the efficacy and safety of intranasal esketamine as maintenance antidepressant therapy in patients who have demonstrated clinical improvement with off-label intravenous racemic ketamine for…
- Trial name
- NCT04856124
- Testing
- Intranasal esketamine
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Psych Atlanta
Major Depressive Episode, Major Depressive Disorder
Patient-oriented Randomized Pragmatic Feasibility Trial With rTMS in Depression and Anxiety
This trial compares intermittent theta-burst stimulation (iTBS) to low frequency repetitive transcranial magnetic stimulation (LFR) in regards to depression and anxiety outcomes in 100 patients with treatment resistant depression…
- Trial name
- PORT (NCT05028738)
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University of British Columbia
Major Depressive Disorders
N-Acetyl Cysteine Supplementation in Therapy Refractory Major Depressive Disorders
The aim of this study is to evaluate the efficacy of N-acetylcysteine (NAC) add-on to antidepressant medication in treating patients who do not relieve during standard antidepressant treatment for 6 weeks at least.
- Trial name
- NCT02972398
- Testing
- N-acetylcysteine
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tianjin Anding Hospital
Depression, Depressive Disorder
Assessment of the Safety and Effectiveness of Cortical Stimulation in Subjects With Major Depressive Disorder
The purpose of this study is to assess the safety and effectiveness of cortical stimulation to the cerebral cortex of subjects who have suffered from treatment-resistant depression and have failed routine attempts at controlling…
- Trial name
- PROSPECT (NCT00380042)
- Testing
- Cortical Stimulation
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Northstar Neuroscience
PTSD, Alzheimer Disease
First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)
The goal of this First-In-Human (FIH) trial is to learn about safety and PharmacoKinetics (PK) in healthy adult volunteers. The main questions it aims to answer are: What is the safety of single ascending doses of the…
- Conditions
- PTSD, Alzheimer Disease, Brain Diseases, Neuro-Degenerative Disease
- Trial name
- NCT05921929
- Testing
- Fluoroethylnormemantine (FENM)
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- ReST Therapeutics
Bipolar Disorder
Clinical Trial of Felbamate for Treatment-Resistant Bipolar Depression
The purpose of this study is to evaluate the safety and effectiveness of the drug felbamate for treating depression in patients with bipolar disorder that has not responded to standard treatments.
- Trial name
- NCT00034229
- Testing
- Felbamate
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Institute of Mental Health (NIMH)
Depressive Disorder
An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression
This study will examine whether a highly specific and powerful 5-hydroxytryptamine 2A (5-HT2A) antagonist, M100907, combined with escitalopram, is responsible for an antidepressant effect.
- Trial name
- NCT00070694
- Testing
- MDL100.907
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Institute of Mental Health (NIMH)
Treatment Resistant Depression
An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression
An open-label, multi-centre, Phase 2a study to evaluate the safety, tolerability, and pharmacodynamics of one and two doses of intranasal BPL-003 combined with psychological support, in patients with treatment resistant…
- Trial name
- NCT05660642
- Testing
- BPL-003
- Where
- 3 sites in United Kingdom
- Volunteers
- 72 people
- Sponsor
- Beckley Psytech Limited
Major Depressive Disorder, Depression
Buprenorphine Used With Treatment Resistant Depression in Older Adults
The investigators are conducting a research study to learn about the safety and benefit of using a medication called buprenorphine for patients with difficult to treat depression.
- Trial name
- IRLGreyB (NCT02181231)
- Testing
- venlafaxine XR, buprenorphine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Depressive Disorder, Treatment-Resistant
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression
The purpose of this study is to assess the efficacy of intranasal esketamine plus an oral antidepressant compared with an oral antidepressant (active comparator) plus intranasal placebo in delaying relapse of depressive symptoms…
- Trial name
- SUSTAIN-1 (NCT02493868)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 155 sites in United States, Belgium and 13 more
- Volunteers
- 719 people
- Sponsor
- Janssen Research & Development, LLC
Depression, Insomnia
Cognitive Behavioral Therapy for Insomnia with RTMS
Depression and insomnia occur together in a substantial number of patients. Transcranial magnetic stimulation (TMS) is an effective treatment for depression, but does not help insomnia symptoms in depressed patients.
- Trial name
- NCT04258618
- Testing
- CBT-I (Cognitive Behavioral Therapy for Insomnia) with rTMS, Repetitive Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Medical University of South Carolina
Depression and Quality of Life, Treatment Resistant Depression (TRD)
Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression
This observational study investigates the use of Esketamine Intranasal Spray in patients with Treatment-Resistant Depression in Real-World Settings.
- Conditions
- Depression and Quality of Life, Treatment Resistant Depression (TRD), Anhedonia, Apathy
- Trial name
- ESKPSY (NCT07146503)
- Testing
- Esketamine (Intranasal Spray)
- Where
- 5 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Riccardo Guglielmo
Depressive Disorder,, Treatment-Resistant Depression
Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population
A randomized multicentric parallel arms study involving the use of ketamine for treatment-resistant depression will be held at three national health provider clinics in the Mexican population.
- Trial name
- NCT01868802
- Testing
- Ketamine
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Paul J. Lamothe